Alternatives to Crown Bioscience

A biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services.

Integrated drug development solutions for pharmaceutical and biotechnology companies, from preclinical to clinical trials.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Leap Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel targeted and immuno-oncology therapies.

Physics-based software platform for molecular discovery and design in life and materials sciences.

AI-driven drug discovery spinoff from DeepMind using AlphaFold to discover novel medicines.

Global CRDMO providing integrated R&D and manufacturing services for the pharmaceutical and life sciences industries.

Leveraging quantum mechanics for accelerated molecular simulations in drug discovery.

Atomwise uses AI to accelerate the discovery of novel small molecule therapeutics with its AtomNet platform.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Life science company pioneering drug discovery with AI and advanced technologies.

Mabylon is a biotechnology company focused on developing innovative antibody-based therapies for infectious diseases and cancer.

AI platform for computational biologists to accelerate drug discovery and therapeutic development.

Biopharmaceutical company developing therapies for neurodegenerative diseases, focusing on crossing the blood-brain barrier.

Global contract research, development, and manufacturing organization for pharmaceutical and biopharmaceutical industries.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Biotechnology startup developing next-generation cancer immunotherapies targeting shared tumor-associated antigens.

A global oncology company developing and commercializing innovative cancer treatments.

AI-driven drug discovery platform accelerating breakthrough scientific research.

AI-powered spatial biology platform for precision medicine and drug development.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

AI-powered platform for profiling cancer biomarkers from digitized biopsy images.

Developing microbiome-derived therapies to overcome resistance to immune checkpoint inhibitors in cancer treatment.

Developing engineered biologics to harness the immune system for disease treatment.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Lunit is a medical AI company developing AI-powered solutions for cancer diagnostics and therapeutics.

Mapping cell-cell communication at scale in human tissue.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.

Developing novel therapeutics targeting dysfunctional DNA packaging for diseases like cancer.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

AI-powered platform connecting cancer patients to advanced treatments and clinical trials.

Clinical-stage precision medicine company using protein motion insights for drug discovery.

Develops antibody-drug conjugates (ADCs) for targeted cancer therapy.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.

Microbiome drug discovery company developing customized phage therapies for chronic diseases.

Precision oncology company developing cancer therapies guided by proprietary functional genomics.

Biotech company using AI and deep RNA analysis to predict cancer treatment response.

AI-powered blood test for early cancer detection and subtyping.

Personalized medicine startup focused on accurate cancer treatment through advanced diagnostics and functional drug sensitivity testing.

A clinical-stage oncology company developing DNA interference (DNAi) based cancer therapies.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

Biotech company developing next-generation gene writing tools for advanced therapies.

Leveraging proteomic pattern analysis to personalize cancer treatment and improve patient outcomes.

Omnix Medical is developing a novel platform for advanced wound care management.

Biotech company using AI and computational platforms to design novel peptide therapeutics.

Biotechnology company developing novel immunotherapies for cancer.

Adimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.

AI-powered insights platform for life sciences and biotech workflows.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Developing novel diagnostics to predict patient response to immunotherapy.